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Background: The essential oil (EO) of Artemisia vulgaris L. has been traditionally used worldwide for treating a large
number of diseases. Although major components in A. vulgaris EO have been shown to inhibit growth of different
cancer cells, as pure compounds or part of other plants extracted oil, no information is known about its anti-proliferative
activities. Therefore, the current investigation has evaluated the toxicity of the plant extracted oil from buds (AVO-b) and
leaves (AVO-l) and characterized their growth inhibitory effects on cancer cells.
Methods: AVO-b and AVO-l from A. vulgaris L. were extracted by hydrodistillation, and their effect on the viability of
human HL-60 promyelocytic leukemia and various other cancer cell lines was tested using MTT assay. Flow cytometric
analysis of apoptosis, DNA fragmentation assay, caspases enzymatic activities and Western blotting were used to
determine the apoptotic pathway triggered by their action on HL-60 cells.
Results: Low concentrations of AVO-b and AVO-l inhibited the growth of HL-60 cells in a dose- and time-dependent
manner. Employing flow cytometric, DNA fragmentation and caspase activation analyses, demonstrated that the
cytotoxic effect of the oils is mediated by a caspase-dependent apoptosis. Kinetic studies in the presence and absence
specific caspase inhibitors showed that activation of caspase-8 was dependent and subsequent to the activation of
caspases-9 and −3. In addition, the essential oil caused a disruption of the mitochondrial transmembrane potential
(ΔΨm), increased the release of cytochrome c to the cytosol, and altered the expression of certain members of Bcl-2
family (Bcl-2, Bax and Bid), Apaf-1 and XIAP. Interestingly, low doses of AVO-b and AVO-1 also induced apoptosis in
various cancer cell lines, but not in noncancerous cells.
Conclusions: The results demonstrate that the EO-induced apoptosis in HL-60 cells is mediated by caspase-dependent
pathways, involving caspases-3, −9, and −8, which are initiated by Bcl-2/Bax/Bid-dependent loss of ΔΨm leading to
release of cytochrome c to the cytoplasm to activate the caspase cascade. The finding that AVO-b and AVO-l are more
efficient to induce apoptosis in different cancer cell lines than noncancerous cells, suggests that A. vulgaris might be a
promising source for new anticancer agents.
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Cancer is one of the leading causes of death worldwide [1].
Although the current anticancer drugs continue to play a
major role in cancer treatment, there are still many types
of cancers do not respond effectively to the available thera-
peutics. Hence, there is an impetus to identify, develop and
test more potent anticancer therapeutics [2].
One of the key methods of successful chemotherapeu-
tics is their ability to trigger death of cancer cells through
apoptosis [3,4]. These anticancer agents are able to inhibit
cell growth by acting on two principal signaling pathways
of apoptosis. One pathway (the extrinsic/receptor me-
diated) involves ligation of death receptors, such as Fas
receptor (Fas) and other members of the tumor-necrosis
factor (TNF) receptor family, resulting in recruitment and
activation of caspase-8 [5,6]. The second pathway (intrin-
sic/mitochondria dependent) is stimulated by the release
of cytochrome c from the mitochondrial intermembrane
space to the cytosol allowing activation of caspase-9 [7,8].
Following activation of the initiator caspase-8 or −9, the
two pathways converge on the activation of caspase-3,
which finally execute the death process by cleaving various
vital substrates required for cell survival and maintaining
the integrity of the genomic DNA [5]. Although these
pathways are distinct from each other, they cross-commu-
nicate (i.e. activation of one pathway triggers activation of
the other) to amplify the apoptotic signal [9].
Artemisia vulgaris L. (commonly known as mugwort)
belongs to the Asteraceae family of plants, which consists
of more than 500 species that are globally distributed. The
plant is traditionally used to treat a wide range of condi-
tions, including gastrointestinal disorders, headaches, nose
bleeds, muscle spasms, epilepsy, circulatory problems,
menopausal and menstrual complaints, fever, rheumatism,
asthma, gout, infertility, contact dermatitis, bacterial infec-
tions, inflammation, malaria and worm infestations [10,11].
Recently, there has been increasing interest in the use of
essential oils as medicinal agents, because they have been
found to have anticancer potentials through induction of
apoptosis in various cancer cell lines of hematological and
solid tumor origins [12,13]. There is considerable evidence
showing that the active compounds in the essential oils of
different Artemisia species are responsible for their anti-
proliferative effect on cancer cells [14-19]. Although there
is no available scientific data on the cytotoxic and apop-
tosis inducing effects of A. vulgaris essential oil, previous
evidence indicate that the aqueous methanol extract from
dry leaves of this plant is cytotoxic to the human hepato-
cellular carcinoma cell line HepG2 that is suggested to be
mediated by apoptosis [20]. Aqueous extracts from A. vul-
garis have been also reported to induce apoptosis in pros-
tate, breast and colon cancer cell lines [21]. In addition,
extracts from A. vulgaris have been shown to sensitize
MDA-MB-231 and MDA-MB-468 breast cancer cells toTRAIL [22]. In a recent study, we have isolated the essen-
tial oils from A. vulgaris aerial parts (leaves and buds) and
identified its chemical composition using gas chromatog-
raphy (GC)/mass spectrometry (MS) analyses [23]. Our
results have identified 22 compounds in A. vulgaris L.
essential oils which majorly include germacrene D (25%),
caryophyllene (20%), alpha-zingiberene (15%) and borneol
(11%) in the leaf oil, while the buds are rich in 1,8-cineole
(32%), camphor (16%), borneol (9%), and caryophyllene
(5%). Major components of the oil such as caryophyllene
[24], alpha-zingiberene [25], borneol [26] and ar-curcu-
mene [27] all have been reported to induce apoptosis in
different human cancer cell lines, as purified compounds
or as part of essential oil isolated from other plants.
In this study, we have examined whether or not the es-
sential oil isolated from the aerial parts of A. vulgaris L. in-
duces apoptosis in the human acute myelogenous leukemia
cell line HL-60. This report has also investigated the pos-
sible mechanism (s) of apoptosis triggered by the essential
oil. The results demonstrate, for the first time, that low
doses of essential oil from A. vulgaris L. induce apoptosis
in the HL-60 cells through a mitochondria and caspase-
dependent mechanisms. In addition to the effect on HL-
60, low concentrations of the essential oils from leaves and
buds were able to induce apoptosis in various other cancer
cell lines, such as Jurkat, K562, MCF-7, HepG2, PC-3 and
HeLa, but lack substantial cytotoxicity for normal non-






zimidazolocarbocyanine iodide), protease inhibitors (PMSF,
pepstatin A, leupeptin, and aprotinin) and etoposide
[4′-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-β-
D-glucopyranoside)] were acquired from Sigma Aldrich
(St Louis, MO, USA). Cell culture media (RPMI 1640 and
DMEM), penicillin-streptomycin, and fetal bovine serum
(FBS) were purchased from Invitrogen (Invitrogen, Carlsbad,
CA, USA). The colorimetric tetrapeptide substrates for
caspase-8 (Ac-IETD-pNA), caspase-9 (Ac-LEHD-pNA)
and caspase-3 (Ac-DEVD-pNA) were purchased from
Calbiochem (San Diego, CA). Caspase-8 inhibitor (zIETD-
fmk), caspase-9 inhibitor (zLEHD-fmk), caspase-3 inhibitor
(zDEVD-fmk), and the general caspase inhibitor (zVAD-
fmk) were obtained from Alexis Corporation (Switzerland).
The polyclonal or monoclonal antibodies against caspase-
8, cytochrome c, Apaf-1, XIAP, α-tubulin, β-actin, VDAC,
Bax, Bak, Bcl-2 and Bcl-xL proteins were obtained from
Santa Cruz Biotechnology (CA, USA), while the ones for
caspase-9 and caspase-3 are from Stressgen Biotechnolo-
gies (Victoria, British Columbia, Canada).
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Fresh Artemisia vulgaris L. plants were collected during
July 2010 through August of 2010 from Erie, Pennsylvania
in the United States of America. The plant identity was
confirmed by Dr. Marlene Cross, Department of Biology,
Mercyhurst University, and a reference voucher specimen
(Reference number: TREC He- 00818) was deposited in
the Herbarium of the Tom Ridge Center, Erie, Pennsylvania
[23]. In addition, the identity of the same plant used in
this study was further confirmed using DNA sequencing
as recently described by [28]. The leaves and buds (be-
fore flowering) were washed, separated and dried before
further analysis.Isolation of essential oils
We have previously described the isolation and chemical
composition of essential oils from A. vulgaris aerial parts
[23]. Briefly, 334 g of macerated A. vulgaris buds were in-
troduced into a two liter round bottom flask and soaked
in 1.68 L double distilled water. The flask material was
subjected to hydrodistillation using a Clevenger-type ap-
paratus. Approximately, 966 mg of the bud’s essential oil
(AVO-b) was collected after four hours. A similar proced-
ure was followed to extract the essential oil from the plant
fresh leaves (600 g); which yielded 560 mg of light yellow
oil (AVO-l). Both samples of AVO-l and AVO-b were
aliquoted in small glass tubes (50 μg each) and stored
at −20°C, but allowed to warm to room temperature be-
fore addition to cultured cells. The density of AVO-l was
0.909 g/mL and 0.947 g/mL for AVO-b. Proper dilutions
of the oils were performed using a 25% DMSO in phos-
phate buffered saline (PBS).Cell culture conditions
The human acute promyelocytic leukemia HL-60 (ATCC®
CCL-240™), Jurkat (human acute T lymphocytic leukemia,
ATCC® TIB-152™) and K-562 (human chronic myeloge-
nous leukemia, ATCC® CCL-243™) suspension cells were
maintained in RPMI-1640, while HepG2 (human hepato-
cellular carcinoma, ATCC® HB-8065™), MCF7 (human
breast adenocarcinoma, ATCC® HTB-22™), PC-3 (human
prostate adenocarcinoma, ATCC® CRL-1435™), HeLa
(human cervical Adenocarcinoma, ATCC® CCL-2™), HEK-
293 (human embryonic kidney, ATCC® CRL-1573 ™), BJ
(human skin fibroblast, ATCC® CRL-2522™ ) and V79-4
(Chinese hamster lung fibroblast, ATCC® CCL-93™) ad-
herent cells were cultured in DMEM medium supple-
mented with 10% (V/V) heat inactivated FBS, penicillin G
(100U/mL) and streptomycin (100 mg/mL) at 37∘C in a 5%
CO2 humidified incubator. The media were changed 2–3
days and subcultured when the cell population density
reached to 70–80% confluence. Cells were seeded at an ap-
propriate density according to each experimental design.Cell viability (cytotoxicity) assay
The cell viability was assessed using the MTT assay [29].
Briefly, 5 × 104 of HL-60, in a 100 μL of RPMI-1640
medium were seeded in each well of a 96 well-plate.
After 24 h, increasing concentrations of AVO-l or AVO-
b (0.0 to 2.0 μg/mL) were added and incubated for 24 h
in a 5% CO2-cell culture incubator. Alternatively, cul-
tured cells were incubated with 1.0 μg/mL of AVO-l or
AVO-b for different time-points (0, 4, 8, 12, 24, 36 and
48 h) before analysis. At the end of incubation period
with the oil, 50 μL of MTT (2 mg/mL stock solution)
were added and the plates and incubated for an
additional 4 h. The resulting MTT-formazan product
was dissolved by addition of 100 μL of DMSO and incu-
bation was continued for additional 4 h. The amount of
formazan was determined by measuring the absorbance
at 570 nm using an E Max Precision Microplate reader
(Molecular Devices, Sunnyvale, CL, USA). The concen-
tration of the essential oil leading to 50% inhibition of
viability (IC50) was calculated using non-linear regres-
sion analysis of GraphPad Prism 5 software. When cas-
pase inhibitors were used, HL-60 cells were incubated
with either 35.0 μM of Caspase-8 inhibitor (zIETD-
fmk), caspase-9 inhibitor (zLEHD-fmk), caspase-3 in-
hibitor (zDEVD-fmk), or 50.0 μM of the general caspase
inhibitor (zVAD-fmk) for 6 h prior to addition of the ex-
tracted oil. In all experiments, the final concentration of
DMSO was ≤ 0.05%. Similar concentrations of DMSO
were added to the control of untreated cells, and showed
no effect on cell viability, when compared to the viabil-
ity of cells without DMSO. Under similar conditions,
HL-60 cells were treated with 4.0 or 8.0 μM etoposide
as a positive control to validate the results of MTT
assay.
Analysis of apoptosis by flow cytometry
The percentage of cells undergoing apoptosis after treat-
ment with increasing concentrations of A. vulgaris oil
essential oil (AVO) was determined by using the Muse™
Annexin V & Dead Cell Assay kit (EMD Millipore
Bioscience, Darmstadt, Germany) according to the manu-
facturer’s protocol. The kit utilizes a fluorescent dye (FITC)
conjugated to Annexin-V to detect phosphatidylserine (PS)
on the external membrane of apoptotic cells and 7-AAD
(7-amino-actinomycin D) as a dead cells marker. 7-AAD is
excluded from living healthy cells, as well as early apoptotic
cells. Percentages of cells in early (Annexin-V+ve/7-AAD-ve)
and late stages of apoptosis (Annexin-V+ve/7-AAD+ve) were
determined by a flow cytometer-based instrument (Muse™
Cell Analyzer, EMD Millipore Bioscience). In all experi-
ments, the solvent DMSO concentration was ≤ 0.05%.
Similar concentrations of DMSO were added to the
control of untreated cells, and showed no effect on trig-
gering apoptosis, when compared to cultured HL-60
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treated with 8 μM etoposide as a positive control to val-
idate the apoptosis results.Detection of DNA fragmentation
DNA fragmentation was analyzed using agarose gel elec-
trophoresis. Genomic DNA was prepared using the
method previously described in details by [30,31] with
slight modifications. After treating 2 × 106 cultured HL-60
cells with increasing concentrations of AVO-l or AVO-b
for 24 h, cells were harvested by centrifugation at 500 g
for 5 min, and washed twice with 1.0 mL PBS. The pel-
leted cells were subsequently lysed in a buffer containing
50 mM Tris–HCl, pH 8.0, 10 mM EDTA, 0.5% SDS and
0.5 mg/mL proteinase K at room temperature for 30 min.
The mixtures was treated with RNase A (25 mg/mL) at
37°C for 30 min. The DNA was extracted and purified se-
quentially with phenol: chloroform (1:1) and chloroform
followed by precipitation in 100% ice-cold ethanol. The
samples were then air dried and resuspended in TE buffer
(10 mM Tris HCl, 1 mM EDTA, pH 7.5). 5.0 μg of each of
DNA samples were resolved by electrophoresis for 4 h
on a 1.5% agarose gel and stained with ethidium brom-
ide and the banding patterns were visualized with the
Foto/Eclipse UV transilluminator. The presence of late
apoptosis events were indicated by the appearance of a
ladder of oligonucleosomal DNA fragments which are
approximately 180–200 bp multiples. A DNA size maker
was used as a molecular size standard.Assays of caspase-9, −8, and −3 activities
The activities of caspase-9, −8, and −3 in HL-60 cell lysates
(30 μg), obtained after treating with the proper concentra-
tion of AVO-l or AVO-b for the desired time periods in the
presence or absence of the specific caspase inhibitors, were
determined spectrophotometricaly at 405 nm using a mi-
crotiter plate reader. The assays were performed by incu-
bating the cell lysates with 0.2 mM of the caspase-specific
colorimetric tetrapeptide substrates, Ac-LEHD-pNA (for
caspase-9), Ac-IETD-pNA (for caspase-8) or Ac-DEVD-
pNA (for caspase-3) for 1 h at 37°C as described by [31].
The increase in the absorbance at 405 nm which corre-
sponds to the amount of p-nitroaniline (pNA) liberated
from the peptide substrates was converted into units of
enzyme activity using a standard curve generated with
free pNA. One unit of caspase-3, −8, or −9 activity cor-
respond to the amount of enzyme that will release 1
pmol of pNA from 0.2 mM DEVD-pNA, IETD-pNA or
Ac-LEHD-pNA per min, respectively. Lysates from HL-
60 cells treated with etoposides were also used in these
assays as positive control to validate the enzymatic
assays.Assessment of changes in mitochondrial transmembrane
potential
Measurement of changes in mitochondria membrane po-
tential (ΔΨm) was performed with the fluorescent stain
JC-1. This dye accumulates in mitochondria in an MMP
(mitochondria membrane potential)-dependent manner,
showing red fluorescent JC-1 aggregates (590 nm emis-
sions) at higher MPP. When MMP decreases, JC-1 aggre-
gates disappear from mitochondria and change to green
fluorescent JC-1 monomers (535 nm emissions). There-
fore, the ratio of the red signal to the green can been used
to detect the changes of MMP (ΔΨm) due to depo-
larization in the early stages of cell death as a result of
mitochondrial damage [32,33]. Measurement of mito-
chondria ΔΨm in AVO-treated cells was performed as
previously described in [34] with some modifications.
Briefly, after treating the HL60 cells with AVO-l or AVO-
b for different periods of time, cells were incubated at
room temperature in the dark with 5 μg/mL JC-1 in HBSS
(Hank’s balanced salt solution, Invitrogen, USA) for 30 mi-
nutes. The cells were then washed twice with HBSS and
fluorescence levels were immediately acquired with excita-
tion and emission wavelengths set at 535 and 590 nm,
respectively, for red fluorescence, and 485 and 535 nm, re-
spectively, for green fluorescence. Measurements were
performed in a 96-well plate using a fluorometer plate
reader (FLUOstar OPTIMA F microplate fluorometer,
BMG LABTECH GmbH, Germany). For each sample, the
results were calculated as the ratio (red/green) of fluores-
cence of sample, averaged after the fluorescence values
had been corrected for the background. HL-60 cells
treated with etoposide were used as positive controls to
validate the fluorometry results. In all experiments, the
solvent DMSO concentration was ≤ 0.05%. Similar con-
centrations of DMSO were added to the control of un-
treated cells, and showed no effect on triggering changes
in mitochondria transmembrane potential, when com-
pared to cultured HL-60 cells in the absence of DMSO.
Isolation of mitochondrial and cytosolic fractions
Mitochondrial and cytosolic fractions from HL-60 cells were
prepared by differential centrifugation at 4°C as previously
described [35,36]. Briefly, The pellets of AVO-b-treated cells
were washed twice with PBS (pH 7.4) and resuspended in a
5 volumes of buffered-medium containing 70 mM sucrose,
220 mM mannitol, 2.5 mM Hepes, pH 7.4, 2 mM EDTA,
1 mM DTT, and 0.1 mM PMSF. Subsequently, the cells
were homogenized in a glass Dounce homogenizer (20
strokes). The homogenates were centrifuged twice at 600 g
for 10 min to remove nuclei and debris. The resulting
supernatant was further centrifuged at 12,000 g for 15 min
and the mitochondria, recovered in the pellets, were washed
and resuspended in the same buffered-medium. The super-
natant was used as the cytosolic fraction.
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In vivo release of cytochrome c from mitochondria into
the cytoplasm of AVO-b-treated HL-60 cells was de-
tected by probing the electrophoresed mitochondrial
(30 μg) or cytosolic (50 μg) fractions, after blotting their
proteins onto a PVDF membrane, with anti-cytochrome
c antibody as previously described [35].
Western blot analysis
AVO-treated HL-60 cells were harvested by centrifugation
at 500 g, washed twice with PBS, and suspended in a lysis
buffer containing 100 mM Hepes, pH 7.4, 10% sucrose,
10 mM DTT, 0.1% CHAPS, 150 mM NaCl, and protease
inhibitors (1 mM PMSF and 1 μg/mL each leupeptin,
aprotinin, and pepstain A). The cells were lysed by four
repeated cycles of freeze/thawing (in dry ice/37°C water
bath) and were then centrifuged at 4°C for 30 min at
14,000 g. The supernatant was collected and stored
at −80°C or used immediately. The lysates were analyzed
for total protein by a protein assay kit, based on the colori-
metric reaction of Bradford protein assay (from Bio-Rad
Laboratories Inc., CA, USA). Protein samples (50 μg/well)
were separated on 10% or 12% SDS–polyacrylamide gels
and electroblotted onto a PVDF membrane (Millipore
Corp., MA, USA). Western blot analyses for caspases,
cytochrome c, members of the Bcl-2 family proteins,
Apaf-1 and XIAP were previously described in our pub-
lications [31,35]. To confirm equal loading of proteins in
gels, the blots were also immunoprobed with a rabbit
polyclonal antibody against the cytoskeletal protein α-
tubulin or β-actin.
Statistical analysis
Data presented are the means ± S.D. of results from a
minimum of three independent experiments with similar
patterns. Statistical analysis was performed using one-
way ANOVA and Student’s t-test. A p < 0.05 value was
considered statistically significant.
Results
AVO induces apoptosis in HL-60 cells
The cytotoxic effect of the essential oil (EO) extracted
from both leaves and buds of Artemisia vulgaris was
examined in HL-60 cells using MTT assays. The EO
from both leaves (AVO-l) and buds (AVO-b) showed a
substantial cytotoxicity in a dose- (Figure 1A) and time-
dependent manner (Figure 1B). Interestingly, AVO-b
showed 10-15% more cytotoxic effect than AVO-l in all
the tested doses and time points. Accordingly, further
experiments were performed to evaluate the effects of
AVO on apoptosis and to identify the molecular mecha-
nisms involved in its effect on HL-60 cells.
To determine whether the cytotoxic effect of AVO
is associated with induction of apoptosis, HL-60 cellswere treated with increasing concentrations of either
AVO-b or AVO-l and then analyzed by a flow cytom-
etry after staining with FITC-annexin-V/7-AAD. This
method has been widely used to distinguish between
normal cells (annexin-V−/7-AAD−), early apoptotic
cells (annexin-V+ve/7-AAD-ve) and late apoptotic cells
(annexin-V+ve/7-AAD+ve). As shown in Figure 2A, a
dose-dependent increase in annexin-V+ve cells was ob-
served after treating with either AVO-b or AVO-l. Quanti-
tative measurement of the percentages of apoptotic HL-60
pre-incubated with 0.25, 0.5, 1.0 and 2.0 μg/mL of AVO-l
were 25.6, 35.4, 68.2 and 81.3%, while the same concentra-
tions of AVO-b resulted in 30.2, 44.6, 82.3, and 94.8%, re-
spectively. The average apoptosis rate produced by AVO-b
was 20% higher than the one induced by AVO-l and, thus,
coincided with the demonstrated effect by MTT assay.
Furthermore, we examined the ability of AVO to trigger
the formation of a typical internucleosomal DNA ladder-
ing pattern, as an indication for later apoptotic stages. As
shown in Figure 2B, both essential oils from A. vulgaris in-
duced DNA fragmentation in HL-60 cells in a dose-
dependent manner. A clear DNA ladder fragmentation
was detected after exposure of HL-60 cells to 1.0 μg/mL
of AVO-b and 2.0 μg/ml of AVO-l for 24 h. Taken to-
gether, these findings indicate that the AVO-induced cell
death in HL-60 cells is due to apoptotic rather than nec-
rotic effect.
Role of caspases in AVO-induced apoptosis in HL-60 cells
Apoptosis induced by various cytotoxic agents is highly
dependent on the activation of caspases, which play
pivotal roles in cleaving specific target proteins [5]. To fur-
ther characterize the AVO-triggered apoptosis, we exam-
ined whether treatments with the AVO-b and AVO-l lead
to processing and subsequent activations of caspases in
HL-60 cells. Therefore, cells were exposed to increasing
concentrations of the EO for 24 h, and then analyzed for
caspase processing by Western blotting (Figure 3A),
and their enzymatic activation by colorimetric assays
(Figure 3B). As shown in Figure 3A, the processing (acti-
vation) of initiator caspase-8 and −9 and the effector
caspase-3 were demonstrated by the decrease in the levels
of procaspase forms and the appearance of their corre-
sponding cleaved bands after immunoblotting with their
respective antibodies . The processing of these caspases
increased after exposure of the HL-60 cells to the AVO-b
and AVO-l in a dose-dependent manner, with maximum
levels occurred after exposure to 2.0 μg/ml of AVO-b or
AVO-l. The processing of caspases coincided with the
demonstrated dose-dependent fragmentation of DNA
(Figure 2B). Processing of these caspases was associated
with their activation. As shown in Figure 3B, the AVO-l
and AVO-b were found to trigger a dose-dependent in-
crease in the specific activities of the initiator caspase-8
Figure 1 AVO inhibits the growth of HL-60 cells in a dose- and time-dependent manner. (A) HL-60 cells were treated with varying
concentrations of AVO-l or AVO-b (0.0 to 2.0 μg/mL) for 24 h and the viability was analyzed by MTT assay as described in the methods. (B) HL-60
cells were incubated with 1.0 μg/mL of either AVO-l or AVO-b for different periods of time (0 to 48 h) and cell viability was assessed by the MTT
assay. The control represents cells incubated under similar conditions in the absence of essential oil. The percentage of cell viability in each
sample was expressed relative to untreated control, which was considered as a 100%. HL-60 cells were also treated with 8.0 μM etoposide under
similar conditions as positive controls. The results shown represent the mean ± SD of three independent trials. Statistical analysis showed that all
samples are significantly different (p < 0.05), when compared to untreated control without AVO or etoposide.
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values (2.28 ± 0.12, 1.05 ± 0.08 and 1.41 ± 0.14 pmol pNA/
min/mg protein, respectively) after incubating HL-60 cells
with a concentration of 2.0 μg/mL of AVO-l for 24 h.
Under similar experimental conditions, the AVO-b also
induced the activations of these three caspases in a dose-
dependent fashion, and reached a mean specific activity
peak values at a concentration of 1.0 μg/mL of cultured
cells for caspase-8 (2.68 ± 0.07 pmol pNA/min/mg pro-
tein) and 2.0 μg/mL for both caspase-9 and −3 (1.28 ±
0.09 and 1.83 ± 0.11 pmol pNA/min/mg protein, respect-
ively). In all the tested doses, the AVO-b was able to in-
duce a 20% to 35% more activation of these caspases than
AVO-l. These data support the finding in Figures 1 and 2
that AVO-b is more toxic to cells than AVO-l. Interest-
ingly, concentrations above 2.0 μg/ml of either oils did not
show higher levels of caspases specific activities (data not
shown).
To further confirm the involvement of caspases in
AVO-induced apoptosis, various specific caspase inhibi-
tors, namely, z-LEHD-fmk (caspase-9 inhibitor), z-IETD-
fmk (caspase-8 inhibitor), z-DEVD-fmk (caspase-3 inhibi-
tor), and z-VAD-fmk (a general caspase inhibitor), were
used at concentrations that completely blocked the activa-
tions of their corresponding caspases. HL-60 cells were in-
cubated with the respective inhibitors for 6 hours prior to
addition of the EO. As shown in Figure 3C, z-LEHD-fmk,
z-IETD-fmk, z-DEVD-fmk and z-VAD-fmk all substan-
tially suppressed the induced-cytotoxicity of AVO-l/AVO-
b by 81.65%/77.14%, 70.93%/64.76%, 76.85%/72.33% and
89.30%/91.71%, respectively. Similarly, pre-incubating the
cells with z-VAD-fmk completely inhibited the associated
apoptosis changes induced by treating HL-60 cells witheither AVO-l or AVO-b, such as the appearance of
nnexin-V+ve cells and DNA fragmentation (data not
shown). These results imply that AVO-l and AVO-b in-
duce apoptosis through a caspases-dependent pathway
in HL-60 cells.
To determine the signaling events involved in the
AVO-induced activation of caspase cascades, we exam-
ined the effects of AVO-b on the kinetics of the activa-
tion of caspases-9, −8, and −3. As shown in Figure 4A,
caspase-9 activation was detected at 4 h after oil treat-
ment, whereas caspase-3 activation was evident at 8 h
and caspase-8 activation was notable only at 16 h. The
increased activities of caspase-9, −8, and −3 peaked at
48 h after exposure of the cells to the oil. These findings
suggest that AVO signals activation of caspase-9 initially,
which subsequently stimulates caspase-3 enzymatic ac-
tivity, which then initiates caspase-8 activation to amp-
lify the apoptosis cascade.
Caspase-8 activation can be triggered by a caspase-3-
dependent feedback amplification loop of caspase cas-
cades [37]. Therefore, we analyzed whether caspase-9
and caspase-3 activation is required for the activation of
caspase-8 in AVO-b-treated HL-60 cells. As shown in
Figure 4B, pre-incubation with z-LEHD-fmk (caspase-9
inhibitor) and z-DVED-fmk (caspase-3 inhibitor) mark-
edly abolished the AVO-b-stimulated processing and ac-
tivation of caspase-8. These results indicate the critical
role caspae-9 and −3 in the AVO-induced apoptosis.
Induction of mitochondrial death pathway by AVO in
HL-60 cells
The activation of caspase-9 by AVO suggests that the
mitochondrial apoptotic pathway is triggered in HL-60
Figure 2 The growth inhibitory effect of AVO on HL-60 cells is mediated by apoptosis. (A) Cultured HL-60 cells were treated with varying
concentration of AVO-b or AVO-l (0.0 to 2.0 μg/mL) an apoptosis was analyzed by a flow cytometer after staining with FITC-annexin-V and 7-AAD.
The scattered blots showing the percentages of early and late apoptosis are indicated for one experiment. The graph represents the summary
mean percentages of apoptosis (early and late apoptosis) of two independent experiments for each concentration of the oil. HL-60 cells were
treated with 8.0 μM etoposide as a positive control. Statistical analysis showed that all samples are significantly different (p < 0.05), when compared to
untreated controls. (B) Genomic DNA was extracted from HL-60 cells treated with the different concentrations of AVO-l or AVO-b, and applied
to agarose gel electrophoresis. DNA fragmentation in the gel was visualized by UV light after staining with ethidium bromide. Mark, is a DNA
ladder marker.
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changing its outer and inner membrane permeability and
thus leading to cytochrome c release and caspases activa-
tion [38]. To explore whether the AVO-induced apoptosis
occurs via the mitochondrial signaling pathway, we mea-
sured the effect of AVO-b and AVO-l on disruption of the
mitochondrial membrane potential using the specific
fluorescent dye JC-1. HL-60 cells treated with the AVO-b
or AVO-l at a concentration of 1.0 μg/mL were found to
demonstrate a loss of fluorescence intensity (red/green)
with time (Figure 5A). A marked drop in the relative fluor-
escence was evident after 4 h incubation with the AVO-b,whereas the change in the relative fluorescence was noted
after 6 h in cells treated with the AVO-l. These results in-
dicate that both oils induce a loss of mitochondrial mem-
brane potential.
Activation of the mitochondrial death pathway can
also be identified by the release of mitochondrial cyto-
chrome c. After cytochrome c is released from the mito-
chondria, it can bind to deoxyadenosine triphosphate
(dATP) and Apaf-1, and activate caspase-9 and caspase-
3 [7,8]. We, therefore, investigated the release of cyto-
chrome c from the mitochondria into the cytosol by
Western blotting. Cytosolic cytochrome c was detected
Figure 3 The apoptotic effect of AVO is mediated by activation of caspase cascades. (A) Whole cell extracts (50 μg), from HL-60 cells after
treatment with varying concentrations of AVO-l or AVO-b for 24, were analyzed by Western blotting with antibodies against caspase-8 and −9
and caspase–3, respectively. The unprocessed forms of procaspase-8, −9 and −3, and their respective cleavage products of the active enzymes
are indicated. The same membranes were also probed with an antibody against β-actin as a loading control. (B) Extracts (30 μg proteins) from
cells treated with varying concentrations of AVO-l or AVO-b were analyzed for caspase-8, −9 and −3 catalytic activities using specific colorimetric
tetrapeptide substrates. The specific enzyme activities, which represent the mean ± SD of three independent experiments, were measured as
described in the methods. HL-60 cells were treated with 4.0 and 8.0 μM etoposide as positive controls. Statistical analysis showed that all samples
are significantly different (p < 0.05), when compared to their untreated control. (C) HL-60 cells were incubated with either 35 μM of Caspase-8
inhibitor (z-IETD-fmk), caspase-9 inhibitor (z-LEHD-fmk), caspase-3 inhibitor (z-DEVD-fmk), or 50 μM of the general caspase inhibitor (z-VAD-fmk)
for 6 h prior to addition of 1.0 μg/mL AVO-l or AVO-b for 24 h. After incubation, cell viability was assessed by the MTT assay. The cell viability for
each sample treated with the specific caspase inhibitor was expressed as percentages relative to the parallel control cells incubated with the same
caspase inhibitor alone, without the essential oil, which was considered 100%. The results shown represent the means ± SD of three independent
experiments. Statistical analysis showed that all samples treated with caspase inhibitors and AVO are significantly different (p < 0.05), when
compared to samples treated with the specific caspase inhibitor alone, AVO alone or untreated control.
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tions of AVO-b (Figure 5C) in HL-60 cultured cells, and
the levels of cytochrome c that remained in the mitochon-
dria was observed to decrease concomitantly (Figure 5C).
Cytochrome c release from mitochondria is a critical
step in apoptosis, and earlier investigations had shown
that ionizing radiation (IR) and etoposide induced the
release of cytochrome c from mitochondria in two dis-
tinct stages [39]. At the early stage, low levels of cyto-
chrome c are released from mitochondria and activate
caspases-9 and −3. In contrast, the late stage cytochrome
c release leads to a drastic loss of mitochondrial cyto-
chrome c and is associated with a reduction of the ATPlevels and mitochondrial transmembrane potential. After
accumulation, cytochrome c is progressively degraded by
caspase-like proteases [40]. Indeed, our immunoblotting
analysis showed a small amount of earlier cytochrome c
release after 4–6 h exposure to AVO-b. The amount of
cytochrome c released to the cytosol increased reaching
a peak at 16 h indicating the late stage of heavily loss of
mitochondrial pool of this protein (Figure 5B). The grad-
ual disappearance of cytochrome c from the cytosol at
later hours (24–48 h) could be due to its degradation by
caspase-like proteases [40]. The ability of AVO-b to re-
lease cytochrome c from mitochondria to the cytosol of
HL-60 treated cells in concentration-dependent manner
Figure 4 AVO-b-induced processing and activation of caspase-8 in HL-60 cells requires activation of caspase-9 and −3. (A) HL-60 cells
were treated with 1.0 μg/mL AVO-b for different time intervals (0 to 48 h), and caspase-9 (▲), caspase-8 (■) and caspase-3 (●) activities were
determined calorimetrically and expressed as relative percentages to the control untreated cells. The data shown represent the means ± SD of
two independent trials for each time point. (B) AVO-b-induced caspase-8 activation in the presence and absence (−) of 35 μM specific caspase-8
inhibitor (z-IETD-fmk), caspase-9 inhibitor (z-LEHD-fmk), caspase-3 inhibitor (z-DEVD-fmk), or 50 μM of the general caspase inhibitor (z-VAD-fmk).
HL-60 cells were incubated with each of the individual caspase inhibitor for 6 hours before the exposure to 1.0 μg/mL AVO-b for an additional
24 h. Caspase-8 activation was analyzed calorimetrically after addition of the substrate Ac-IETD-pNA (the graph) and by immunoblotting with a
specific anti-caspase-8 antibody (the Western blot). The results shown represent the percentages of caspase-8 activity relative to the control cells
treated with AVO-b alone (−). “Cont.”, represents caspase-8 activity in HL-60 of untreated cells. Results of caspase-8 activity represent the means ±
SD of three indecent trials. Statistical analysis showed that all samples treated with specific caspase inhibitors and AVO-b are significantly different
(p < 0.05), when compared to cells treated with AVO-b alone.
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tract specifically target the mitochondrial pathway of
apoptosis. AVO-l also induced a decrease of mitochon-
drial cytochrome c in a similar fashion to the AVO-b,
but the amount of cytosolic cytochrome c that wasFigure 5 AVO induces disruption of mitochondrial transmembrane po
cytoplasm and modulates the expression of Apaf-1 and XIAP protein
for different periods of time (0–24 h) and changes in mitochondrial memb
of the fluorescent stain JC-1. Cells treated with 8.0 μM etoposide for 12 and
mean ± SD of three independent experiments. **Represents samples that a
AVO untreated cells. (B) Western blot analysis of cytochrome c in the cytos
points (0 to 48 h) as indicated at the top of each lane. (C) Western blot an
cytochrome c in cytosolic (Cyt.; 50 μg) and mitochondrial (Mit.; 30 μg) fract
of AVO-b (0.0–2.0 μg/mL). The same Western blots in both (B) and (C) for
antibodies to α-tubulin and β-actin, respectively, to ensure equal protein loinduced by AVO-l was lesser than that induced by
AVO-b and started to appear at 8 h after exposure to
the oil (data not shown). This may be attributed to dif-
ferences in the constituents or their concentrations in
the two oils [23].tential (ΔΨm), promotes the release cytochrome c to the
s in HL-60 cells. (A) HL-60 cells treated with 1.0 μg/ml AVO-l or AVO-b
rane potential was monitored by a flourimetric analysis after addition
24 h were used as positive controls. The results shown represents the
re statistically different, when compared to their controls at 0 time or
olic fraction (50 μg) of HL-60 cells treated with AVO-b for different time
alysis of Apaf-1 and XIPA in whole cell extracts (W.E; 50 μg), and
ions obtained from HL-60 cells treated with varying concentrations
the cytosolic fractions and whole cell extracts were probed with
ading in the different lanes.
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1apoptosome, which subsequently triggers activation of
the downstream executioner caspase-3 [7,8]. As shown in
Figure 5C, levels of Apaf-1 were elevated after exposure
of HL-60 cells to increasing concentrations of AVO-b,
whereas the levels of the mitochondria-induced apop-
tosis inhibitor XIAP [41] decreased, and thus further
supporting the involvement of the mitochondrial path-
way in AVO-triggered apoptosis.
Since Bcl-2 family proteins are known to control a
mitochondria-mediated apoptosis pathway by maintain-
ing a balance between pro- and anti-apoptotic members
[9], we examined the effects of AVO-b on the expression
levels of Bcl-2 family proteins in HL-60 treated cells
(Figure 6). Our results showed that AVO-b compounds
decreased the cytosolic levels of pro-apoptotic Bid, but
increased the levels of t-Bid in mitochondria. Further-
more, exposure of HL-60 to the oil increased the expres-
sion of Bax and its translocation to mitochondria in a
dose-dependent manner (Figure 6). On the other hand,Figure 6 AVO-b modulates the expression of Bcl-2 family proteins, an
of HL-60 cells in a dose-dependent manner. Whole cell extracts (50 μg)
from HL-60 cells treated with AVO-b as described above. W.E were probed
were immuneblotted with antibodies against t-Bid, Bax and VDAC, while C
Western blots for the Cyt. fractions and W.E were probed with antibodies tthe amount of the anti-apoptotic protein Bcl-2 was ob-
served to decrease dramatically after treatment with
AVO-b (Figure 6). In contrast, the expression of proa-
poptotic protein, Bak, the anti-apoptotic Bcl-xL did not
change in the presence of the oil. The expression of
VDAC was also not affected by treating AVO-b. These
findings suggest that AVO modulates the protein levels
of Bid, Bax and Bcl-2, and this result in loss ΔΨm and
the release of cytochrome c from mitochondria to the
cytosol.
AVO induces apoptosis in several cancer cell lines
In addition to the effect on HL-60 cells, we have also
evaluated the potential apoptosis-mediated anticancer
potency of AVO on different cancer cell lines. The AVO
inhibited the growth of Jurkat, K562, MCF-7, HepG2,
PC-3 and HeLa cells in a dose dependent manner of
AVO-b (Figure 7A) and AVO-l (Figure 7B). In all the
tested cell lines, AVO-b was more potent inhibitor of
growth than AVO-l. The growth Inhibitory effect of AVOd promotes translocation of Bax and t-Bid to the mitochondria
, mitochondrial (30 μg) and cytosolic (50 μg) fractions were prepared
with antibodies against Bak, Bcl-2 and Bcl-xL proteins. Mit. fractions
yt. fractions were probed with antibodies for Bid and Bax. The same
o α-tubulin and β-actin, respectively.
Figure 7 AVO inhibits the growth of various cancer cell lines by inducing a caspase-dependent apoptosis. Jurkat, K562, MCF-7, HepG2,
PC-3 and HeLa cells were treated with varying concentrations (0.0-2.0 μg/mL) of AVO-b (A) or AVO-l (B) and the viability was analyzed by MTT
assay. The data shown represent the mean ± SD of three independent experiments. (C) Extracts (30 μg proteins) from these cancer cells treated
with 1.0 μg/mL of AVO-b or AVO-l were analyzed for caspase-3 catalytic activities. The specific enzyme activities, which represent the mean ± SD
of three independent experiments, were measured as described in the methods. *p < 0.01 of statistically insignificant values, when compared to
untreated samples.
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caspase-3 in a dose-dependent manner (Figure 7C). Simi-
lar to HL-60, these findings suggest that the antitumor ac-
tivity of AVO is a caspase dependent.
The IC50 values for the AVO-b were 0.5 μg/ml in Jur-
kat, 0.72-0.74 μg/mL in HepG2 and PC-3, 1.0 μg/mL in
K562 and MCF-7 and 2.5 μg/mL in HeLa cells (Table 1).
Interestingly, the IC50 for the normal human skin fibro-
blast (BJ cells), human epithelial kidney cells HEK-293
and the Chinese hamster lung fibroblast V79-4 were
much higher than any of the above cancer cells (17.75
μg/mL and 13.24 μg/mL and 11.25 μg/mL of AVO-b, re-
spectively), suggesting the selectivity of the oil compounds
to inhibit tumor cells (Table 1).
Discussion
Despite the increasing understanding of the biological
processes of cancer development, there is still a strong
need for novel and effective pharmacological strategiesfor intervention with this disease [2]. Pharmacological
agents that induce apoptosis might be effective against
many cancers by inducing death in cancer cells [3,4].
One common and effective strategy for developing novel
chemotherapeutics is the evaluation of natural com-
pounds. In fact, a great number of clinically active drugs
that are used in cancer therapy are either natural products
or based on natural products. Established plant-derived
therapeutics include vinblastine, vincristine, etoposide,
teniposide, paclitaxel, doxetaxel, and camptothecin [42].
Plants from the genus Artemisia L. are phytochemically
important due to their chemical and biological diversity.
Species belonging Artemisia are widespread throughout
the world and most popular in Chinese and other Asian
countries traditional medicine for treatment of various
diseases such as malaria, hepatitis, inflammation, cancer,
and viral, bacterial and fungal infections [10,11]. Extracts
from Artemisia kulbadica, Artemisia diffusa, Artemisia
sieberi, Artemisia santolina and Artemisia turanica all
Table 1 IC50 values of AVO-b in different cell lines
aCell line Origin IC50 AVO-b μg/mL
Jurkat Human Blood T-Cell 0.50
K562 Human Blood B-Cell 1.00
MCF-7 Human Breast 1.00
HepG2 Human Liver 0.72
PC-3 Human Prostate 0.74
HeLa Human Cervical 2.50
BJ human Skin 17.75
HEK-293 Human Kidney 13.24
V79-4 Chinese Hamster Lung 11.25
aThe different cell lines were incubated with increasing concentrations of AVO-
b (0.0 to 20.0 μg/mL) for 24 h. after incubations, the cell viability was assessed
by MTT assay. The IC50 values were determined by using non-linear regression
analysis of GraphPad Prism 5 software.
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[43,44]. Recently, the methanolic extract from Artemisia
vulgaris has been shown to substantially reduces the via-
bility of the hepatocellular carcinoma cell line HepG2
[20]. The cytotoxic effect of this extract is suggested to be
mediated by apoptosis. Extract from A. vulgaris have been
also reported to induce apoptosis in prostate, breast and
colon cancer cell lines [21] and sensitize MDA-MB-231
and MDA-MB-468 breast cancer cells to TRAIL [22].
However, neither the composition of active ingredients
nor the detailed apoptotic mechanisms induced by the dif-
ferent extracts have been determined.
In this report, we show, for the first time, that low
doses of the essential oil, contained in the leaves (AVO-l)
and buds (AVO-b) of A. vulgaris L., induce apoptosis in
HL-60 and various other human cancer cell lines (Jurkat,
K562, MCF-7, HepG2, PC-3 and HeLa), but lacks sub-
stantial cytotoxicity for normal non-malignant mamma-
lian cells such as the human skin fibroblasts BJ and
kidney epithelial cells HEK-293 or the Chinese hamster
V79-4 lung cells at comparable low concentrations. This
feature implies a promising potential of AVO compounds
as chemotherapeutic for cancer treatment with a low risk
of side effects, usually related to the unspecific cytotoxicity
of many conventional cancer therapeutics [4]. AVO de-
creased cell viability after 24 h exposure in a dose-
dependent manner, as assessed by MTT assay in HL-60
and the six other cancer cell lines (Jurkat, K562, MCF-7,
HepG2, PC-3 and HeLa). Moreover, AVO caused cell
death in the HL-60 cell line in a time-dependent manner,
as determined by the same MTT assay. In general, the
cytotoxicity assays of the volatile oil extracted from buds
(AVO-b) showed 10% to 15% more effect than the oil ex-
tracted from leaves (AVO-l) of the plant. This may be due
to differences in the constituents or their concentrations
in the two oils [23].Recent studies have suggested that various extracts
and essential oil from different Artemesia species possess
a chemopreventive potential that is mediated through
apoptosis. The antiproliferative effect of chloroform ex-
tract from Artemisia turanica on HL-60 and K562 can-
cer cells is mediated by apoptosis, whereas the J774
normal cells have not been affected significantly by this
extract [45]. Sesquiterpene lactones compounds derived
from Artemisia douglasiana promote accumulation of
DNA damage markers such as phosphorylated form of
ATM and focal organization of γH2AX and 53BP1,
therefore, triggering cell cycle arrest and apoptosis in
HeLa, S3, MCF-7 and WI-38 cancer cells [46]. The
marked killing effect of certain sesquiterpene lactones
derivatives on cancer cells guided them to clinical trial
studies [47]. In addition, it has been recently shown that
the toxicity of Artemisia annul L. on cultured hepatocarci-
noma cells SMMC-7721 is mainly mediated by apoptosis
[48]. Essential oils of Artemisia capillaris and Artemisia
iwayomogi have been reported to induce apoptosis in KB
human oral epidermoid carcinoma cells via mitochon-
drial stress and caspase activation mediated by MAPK-
stimulated signaling pathway [15].
Cell death may occur by many ways such as necrosis,
autophagy, mitotic catastrophe, senescence and apop-
tosis [49]. For AVO-induced cell death, apoptosis seems
to be way of how cancer cells die. This is supported by
the following findings: first, AVO treated HL-60 cells
showed the morphological aspects associated with early
and late apoptotic events when assessed by flow cytome-
try after staining with FITC-Annexin-V/7-AAD. Second,
AVO induced activation of caspase-3, −8, and −9 that
typically mediate and execute apoptotic cell death. Third,
AVO caused DNA laddering and fragmentation in apop-
totic nuclei of HL-60 cells, a well-recognized process typ-
ically occurring during apoptosis [49]. Fourth, AVO
caused a loss of the mitochondrial ΔΨm and evoked the
release of cytochrome c into the cytoplasm in a dose- and
time-dependent manner, a characteristic for numerous
stimuli that cause apoptosis via the intrinsic pathway in-
volving mitochondria [3,4]. Note that in contrast to cancer
HL-60 cells, AVO up to 10 μg/mL failed to trigger pro-
cessing of caspase-3, −8 and −9, fragmentation of genomic
DNA, and loss of the ΔΨm in non-transformed BJ cells
(data not shown), correlating to the moderate susceptibil-
ity of these cells to AVO-induced cell death. Finally, AVO
failed to evoke apoptosis in HL-60 cells in the presence of
caspase-3, caspase-8 caspase-9 or the general caspases in-
hibitors, implying that a select caspase-dependent path-
way is required to evoke cell death by AVO.
Though the nature of the target of AVO that initializes
apoptosis is unknown, our data suggest that AVO signals
via the intrinsic pathway, rather than the death-receptor/
FADD/caspase-8-mediated signaling route. AVO induced
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increased the expression of Apaf-1, decreased the expres-
sion of XIAP (which inhibits caspase-9 and −3 activation),
required caspase-9 for induction of cell death, activated ef-
fector caspase-3 and caused DNA fragmentation. To-
gether, these events typically signal within the intrinsic
pathway acting downstream the release of cytochrome c
from mitochondria [50-52]. Our findings that substantial
activation of caspase-9 occur earlier than caspase-8 acti-
vation, and that caspase-8 activation was inhibited in
the presence of caspase-9 inhibitor in AVO-treated cells
strongly suggest that the AVO-induced apoptosis occurs
mainly through cytochrome c-dependent activation of
caspase-9 and that activation of caspase-8 is a subse-
quent event to activation of the caspase cascade.
AVO also clearly caused processing of caspase-8, that
usually occurs in response to ligation of death receptors
such as CD95 or the TNFα receptor involving FADD [6].
Since active caspase-8 is capable of inducing the release of
cytochrome c from mitochondria involving cleavage of Bid
to t-Bid and its subsequent translocation to mitochondria
[9], AVO could also affect mitochondria via such a route.
Together, the intrinsic pathway involving mitochondrial
events and caspase-9 virtually contributes to AVO-evoked
cell death, whereas the extrinsic pathway involving death
receptors, FADD and caspase-8 seems to amplify the
apoptotic signal, through increasing the release of cyto-
chrome c to the cytoplasm by cleaving Bid and its subse-
quent translocation to mitochondria [9].
Certainly, the elucidation of the pathways and the re-
spective targets of AVO involved in apoptosis are of
interest. Possible upstream routes and central candidates
for mitochondria-mediated apoptosis that are targeted
by typical cancer agents include the pro-apoptotic factor
p53 and Bcl-2 family of proteins. The pro-apoptotic pro-
tein p53 plays a major role in cellular response to DNA
damage, and when activated leads to cell cycle arrest
and DNA repair or to apoptosis [26,53,54]. p53 protects
cells against cancer transformation and, therefore, many
apoptosis inducing chemotherapeutics depend on func-
tional p53 [55]. Most of human cancers have either muta-
tions or defects in the p53 pathway [53]. HL-60, PC3 and
Jurkat cells that are deficient in functional p53 [53,54,56]
were highly susceptible for AVO, suggesting that AVO in-
duces apoptosis in a p53-independent manner.
The BH3-only proteins act as sentinels for cell stress,
damage or infection, thereby initiating mitochondrial outer
membrane permeabilization by oligomerization of Bax
and/or Bak in the mitochondrial outer membrane forming
channels that permit cytochrome c to escape from the
mitochondria [57]. Since the BH3-only proteins target pro-
apoptotic as well as anti-apoptotic Bcl-2 factors [58], an or-
chestrated interplay of these proteins is important for nor-
mal cell proliferation and cell death, whereas an influenceon a select BH3-only protein may cause an imbalance of
these processes. Our finding that AVO caused a decrease
in the expression of Bcl-2 and increased the translocation
of Bax and t-Bid to mitochondria strongly suggest that the
oil-induced apoptosis involves modulating the expression
of both the anti-apoptotic and pro-apoptotic members of
the Bcl-2 family. AVO may also govern the function of a
pro-apoptotic Bcl-2 member or, on the other hand, may
suppress an anti-apoptotic family member. Alternatively,
AVO may directly act on the mitochondria, hence leading
to loss of the mitochondria ΔΨm and/or allowing cyto-
chrome c to escape from this organelle. Current experi-
ments in our lab address the proximal signaling steps in
AVO-induced loss of ΔΨm and cytochrome c release.
Conclusions
In this study, we have shown for the first time that the
natural ingredients of A. vulgaris EO act as a strong and
selective inducer of apoptosis in various cancer cells
with lower cytotoxicity in normal non-transformed cells.
Obviously, mitochondrial events are the determinants in
AVO-induced cell death, and caspase-9 is a critical elem-
ent in the transduction of the apoptotic signal, whereas
the extrinsic pathway involving death receptors and
caspase-8 is less important. We have recently identified
22 different components in the essential oil or A. Vul-
garis L. [23]. Major components of the oil such as caryo-
phyllene, alpha-zingiberene, borneol and ar-curcumene
all have been reported to induce apoptosis [24-26]. How-
ever, very little is known in scientific research about the
properties of A. vulgaris EO compounds and few studies
have addressed their pharmacological actions. Therefore,
it will be an exciting challenge to further characterize
the pharmacology of A. vulgaris EO compounds and, in
particular, their anticancer pharmacological actions.
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